Cardioprotection of mAb2G4/ODN/lip on Myocardial Ischemia-Reperfusion Injury via Inhibiting the NF-<i>κ</i>B Signaling Pathway

<div>The experimental protocol in vitro. H/R: hypoxia/reoxygenation; LO: ODN/lip at low dose (2 <i>μ</i>g); HO: ODN/lip at high dose (4 <i>μ</i>g); LM: mAb2G4-ODN-lip at low dose (2 <i>μ</i>g); HM: mAb2G4-ODN-lip at high dose (4 <i>μ</i>g); interval: transfer to general culture medium.</div>

Cardiovascular Therapeutics

fig2

Figure 2

Figure 2: Cardioprotection of mAb2G4/ODN/lip on Myocardial Ischemia-Reperfusion Injury via Inhibiting the NF-<i>κ</i>B Signaling Pathway 

Cardiovascular Therapeutics

Cardioprotection of mAb2G4/ODN/lip on Myocardial Ischemia-Reperfusion Injury via Inhibiting the NF-κB Signaling Pathway

Figure 2